LabCorp and Appalachian Regional Healthcare Create Comprehensive Laboratory Collaboration
March 22 2018 - 8:45AM
Business Wire
LabCorp’s Expertise in Health System
Collaborations will Benefit Patients across Eastern Kentucky and
Southern West Virginia
LabCorp® (NYSE: LH) and Appalachian Regional Healthcare have
entered into a multi-year, comprehensive laboratory partnership.
Through the collaboration, LabCorp Diagnostics will provide
technical services for Appalachian Regional Healthcare’s
hospital-based labs, reference testing services for its entire
network of facilities and clinicians, and access to enhanced
information technology and data analytics to help improve the
delivery of patient care.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180322005644/en/
LabCorp, a leading global life sciences company that is deeply
integrated in guiding patient care, provides comprehensive clinical
laboratory and end-to-end drug development services. Appalachian
Regional Healthcare is a not-for-profit health system operating a
network of hospitals, multi-specialty physician practices, home
health agencies, home medical equipment stores, and retail
pharmacies serving communities across Eastern Kentucky and Southern
West Virginia.
“The collaboration between Appalachian Regional Healthcare and
LabCorp Diagnostics will help to provide high-quality, high-value
and standardized laboratory diagnostics for patients and physicians
as well as help Appalachian Regional Healthcare fulfill its mission
to improve the health and promote the well-being of all people in
the region it serves,” said Gary Huff, CEO of LabCorp Diagnostics.
“LabCorp Diagnostics’ industry-leading solutions meet the needs of
health systems and their patients across the entire spectrum of
care. We are grateful for the opportunity to help Appalachian
Regional Healthcare improve health and lives in the communities
where it plays such a critical role.”
“As healthcare continues to evolve and change, Appalachian
Regional Healthcare’s vision to be the most trusted healthcare
provider in the communities we serve is more important than ever,”
Appalachian Regional Healthcare President and CEO Joe Grossman
said. “We continue to grow our system, providing our patients with
a wide range of services that virtually eliminates the need to
leave the area for care. At the heart of all of these services are
our laboratories. We are pleased to partner with LabCorp
Diagnostics to provide our patients the most high-quality and
comprehensive service for which LabCorp is known.”
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a
leading global life sciences company that is deeply integrated in
guiding patient care, providing comprehensive clinical laboratory
and end-to-end drug development services. With a mission to improve
health and improve lives, LabCorp delivers world-class diagnostic
solutions, brings innovative medicines to patients faster and uses
technology to improve the delivery of care. LabCorp reported net
revenues of over $10 billion in 2017. To learn more about
LabCorp, visit www.labcorp.com, and to learn more about
Covance Drug Development, visit www.covance.com.
About Appalachian Regional Healthcare
Appalachian Regional Healthcare is a not-for-profit health
system currently operating 11 hospitals in Barbourville, Hazard,
Harlan, Hyden, McDowell, Middlesboro, West Liberty, Whitesburg and
South Williamson in Kentucky and Beckley and Hinton in West
Virginia, as well as multi-specialty physician practices, home
health agencies, home medical equipment stores and retail
pharmacies. ARH employs nearly 5,000 people with an annual payroll
and benefits of $330 million generated into our local economies.
ARH also has a network of more than 600 active and courtesy medical
staff members. ARH is the largest provider of care and single
largest employer in southeastern Kentucky and the third largest
private employer in southern West Virginia, and is consistently
recognized for its medical excellence.
This press release contains forward-looking
statements about LabCorp’s (the Company) future operations. Each of
the forward-looking statements is subject to change based on
various important factors, including without limitation,
competitive actions in the marketplace, and adverse actions of
governmental and other third-party payers. Actual results could
differ materially from those suggested by these forward-looking
statements. The Company has no obligation to provide any updates to
these forward-looking statements even if its expectations change.
Further information on potential factors that could affect
operating and financial results is included in the Company’s Form
10-K for the year ended December 31, 2017, and subsequent Forms
10-Q, including in each case under the heading risk factors, and in
the Company’s other filings with the SEC. The information in this
press release should be read in conjunction with a review of the
Company’s filings with the SEC including the information in the
Company’s Form 10-K for the year ended December 31, 2017, and
subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180322005644/en/
LabCorpMediaDonald Von Hagen,
336-436-8263Media@labcorp.comorInvestorsScott Frommer,
336-436-5076Investor@labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024